Legend Biotech’s (LEGN) Buy Rating Reiterated at HC Wainwright

Posted by Stanley Muller on Sep 4th, 2026

Legend Biotech (NASDAQ:LEGN – Get Free Report)‘s stock had its “buy” rating reissued by investment analysts at HC Wainwright in a research note issued to investors on Friday, MarketBeat.com reports. They presently have a $65.00 price target on the stock. HC Wainwright’s price target suggests a potential upside of 198.85% from the company’s current price.

LEGN has been the subject of several other research reports. UBS Group restated a “neutral” rating and set a $28.00 price target (down from $49.00) on shares of Legend Biotech in a research report on Monday, July 27th. Raymond James Financial reiterated an “outperform” rating and set a $58.00 price target on shares of Legend Biotech in a research report on Monday, July 27th. Oppenheimer lowered Legend Biotech from an “outperform” rating to a “market perform” rating and lowered their price target for the company from $75.00 to $40.00 in a report on Wednesday, August 12th. Barclays reduced their price objective on shares of Legend Biotech from $80.00 to $78.00 and set an “overweight” rating for the company in a report on Wednesday, August 12th. Finally, Benchmark reissued a “buy” rating on shares of Legend Biotech in a research note on Tuesday, July 28th. Eight equities research analysts have rated the stock with a Buy rating, six have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, Legend Biotech currently has a consensus rating of “Hold” and a consensus price target of $52.29.

Check Out Our Latest Stock Analysis on LEGN

Legend Biotech Price Performance

NASDAQ:LEGN opened at $21.75 on Friday. The firm has a market capitalization of $4.21 billion, a P/E ratio of -87.00 and a beta of 0.40. The business has a 50 day simple moving average of $22.86 and a 200 day simple moving average of $23.54. Legend Biotech has a 12-month low of $16.24 and a 12-month high of $37.50.

Legend Biotech (NASDAQ:LEGN – Get Free Report) last issued its earnings results on Tuesday, August 11th. The company reported $0.09 earnings per share for the quarter, topping the consensus estimate of $0.07 by $0.02. The firm had revenue of $387.50 million for the quarter, compared to analyst estimates of $355.96 million. Legend Biotech had a negative return on equity of 8.71% and a negative net margin of 7.21%.The firm’s revenue for the quarter was up 51.9% on a year-over-year basis. During the same period last year, the company earned $0.03 earnings per share. Research analysts anticipate that Legend Biotech will post -0.05 EPS for the current fiscal year.

Insider Activity at Legend Biotech

In other Legend Biotech news, CEO Ying Huang sold 5,566 shares of Legend Biotech stock in a transaction that occurred on Thursday, June 25th. The shares were sold at an average price of $14.78, for a total transaction of $82,265.48. Following the transaction, the chief executive officer directly owned 241,872 shares in the company, valued at approximately $3,574,868.16. The trade was a 2.25% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. 0.02% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of LEGN. Arrowstreet Capital Limited Partnership increased its stake in Legend Biotech by 343.6% in the 1st quarter. Arrowstreet Capital Limited Partnership now owns 406,901 shares of the company’s stock valued at $7,361,000 after buying an additional 315,176 shares during the period. Y Intercept Hong Kong Ltd purchased a new stake in Legend Biotech in the 1st quarter worth approximately $4,039,000. Renaissance Technologies LLC boosted its stake in shares of Legend Biotech by 29.5% during the 1st quarter. Renaissance Technologies LLC now owns 521,800 shares of the company’s stock valued at $9,439,000 after buying an additional 119,000 shares during the period. Assenagon Asset Management S.A. acquired a new stake in shares of Legend Biotech during the 2nd quarter valued at $55,307,000. Finally, Candriam S.C.A. grew its holdings in shares of Legend Biotech by 79.6% during the 1st quarter. Candriam S.C.A. now owns 470,292 shares of the company’s stock valued at $8,508,000 after acquiring an additional 208,477 shares in the last quarter. Hedge funds and other institutional investors own 70.89% of the company’s stock.

About Legend Biotech

(Get Free Report)

Legend Biotech (NASDAQ: LEGN) is a commercial-stage biopharmaceutical company specializing in the development and commercialization of chimeric antigen receptor T-cell (CAR-T) therapies for oncology. Headquartered in Somerset, New Jersey, with research and development operations in Shanghai, the company leverages a global infrastructure to advance innovative cellular therapies. Legend Biotech pursues a strategy of strategic collaboration to extend its reach, most notably through its partnership with Janssen Biotech, a subsidiary of Johnson & Johnson.

The company’s lead asset, ciltacabtagene autoleucel (commercially marketed as Carvykti), is a B-cell maturation antigen (BCMA)–directed CAR-T therapy for the treatment of relapsed or refractory multiple myeloma.